Navigation Links
Regado Biosciences Presents Positive Data From REG1 Anticoagulation System Phase Ic Study at American Heart Association 2007 Scientific Sessions
Date:11/4/2007

bert A. Harrington, M.D., Professor of Medicine, Duke University Medical Center, and Director, Duke Clinical Research Institute. "I'm looking forward to seeing data from phase II and phase III studies with the REG1 drug:antidote system."

"The data from the Phase 1c study addressed important questions, particularly regarding the ability to titrate the RB007 component and therefore 'dial down' the anticoagulant effect of RB006," stated Doug Gooding, Chief Executive Officer of Regado Biosciences. "Based upon our Phase I study results, we developed an extensive Phase II program to evaluate REG1 in a variety of coronary revascularization settings. The first study is actively enrolling patients and we expect to initiate several additional studies over the coming months."

REVERSAL-PCI, a multi-center, open-label, randomized Phase IIa clinical study of the REG1 anticoagulation system, will enroll 26 patients undergoing elective percutaneous coronary intervention (PCI) to assess whether REG1 can replace standard heparin therapy during the performance of coronary balloon angioplasty dilatation and stenting in patients at low risk for complications associated with therapy-related bleeding or heart attack.

About REG1 Anticoagulation System

Regado's lead product candidate, REG1, is the first specific, direct- acting, antidote-controlled anticoagulant ever described. Regado is developing REG1 for use in patients suffering from acute coronary syndrome who undergo coronary revascularization procedures. These procedures, which include coronary artery bypass grafting (CABG) and percutaneous coronary intervention (PCI), put patients at a high-risk for therapy-related bleeding complications. REG1 is being developed initially to increase therapeutic flexibility and improve patient outcomes in coronary revascularization procedures.

REG1 is a two-component system, consisting of an aptamer-based anticoagulant and its matched antidote. The REG1 anticoagulant co
'/>"/>

SOURCE Regado Biosciences
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. YM BioSciences Announces Secondary Efficacy and Safety Findings in Randomized Phase IIB Aerolef Trial
2. YM BioSciences Announces Preclinical Data Confirming Nimotuzumab Binds to the EGF Receptor and Potentiates Radiotherapy
3. Sangamo BioSciences Announces Presentation of Phase 1 ZFP Therapeutic Data at American Diabetes Association Meeting
4. Neurocrine Biosciences Announces New Research Studies Presented at APSS Reveal Significant Under-Diagnosis of Insomnia
5. Hana Biosciences Presents Data On Two Programs At the American Society of Clinical Oncology Annual Meeting
6. IR BioSciences Announces Promising Data from Study of Its Compound Homspera
7. Sangamo BioSciences Announces Presentation of ZFP Therapeutic Data From Nerve Regeneration Program at American Society for Neural Therapy and Repair Meeting
8. Lux Biosciences Investigational Therapy for Uveitis, LX211, is Subject of Two Presentations at Key Ophthalmology Meeting, ARVO 2007
9. YM BioSciences Reports AeroLEF Randomized Phase IIb Trial Meets Primary Endpoint in Patients with Post-Surgical Pain
10. Hana Biosciences Announces Data to be Presented On Talvesta (Talotrexin) for Injection at The American Association for Cancer Research Annual Meeting
11. Ace Biosciences, Ace393, the Worlds First Commercial Vaccine for Travellers Diarrhoea Caused by Campylobacter Successfully Completes Phase I Clinical Trials
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/31/2014)... STAAR Surgical Company (NASDAQ: STAA ... lenses and delivery systems for the eye today reported ... of $20.0 million, a 10% increase over $18.2 million ... constant currency basis, revenues grew 11% during the second ... 2013.  The effect of foreign currency exchange reduced sales ...
(Date:7/31/2014)... (NYSE: RMD ) today announced results for its ... 2014.  Revenue for the quarter was $415.2 million, flat compared ... decrease on a constant currency basis). Net income was $87.7 ... ended June 30, 2013. Diluted earnings per share for the ... the quarter ended June 30, 2013.  The ...
(Date:7/31/2014)... -- Xencor Inc. (NASDAQ: XNCR ), ... for the treatment of autoimmune diseases, asthma and ... for the second quarter ended June 30, 2014 and ... "In the second quarter, we presented preclinical ... Conference (ATS) demonstrating three novel mechanisms of action ...
Breaking Medicine Technology:STAAR Surgical Reports 10% Second Quarter Revenue Growth 2STAAR Surgical Reports 10% Second Quarter Revenue Growth 3STAAR Surgical Reports 10% Second Quarter Revenue Growth 4STAAR Surgical Reports 10% Second Quarter Revenue Growth 5STAAR Surgical Reports 10% Second Quarter Revenue Growth 6STAAR Surgical Reports 10% Second Quarter Revenue Growth 7STAAR Surgical Reports 10% Second Quarter Revenue Growth 8STAAR Surgical Reports 10% Second Quarter Revenue Growth 9STAAR Surgical Reports 10% Second Quarter Revenue Growth 10STAAR Surgical Reports 10% Second Quarter Revenue Growth 11STAAR Surgical Reports 10% Second Quarter Revenue Growth 12STAAR Surgical Reports 10% Second Quarter Revenue Growth 13STAAR Surgical Reports 10% Second Quarter Revenue Growth 14STAAR Surgical Reports 10% Second Quarter Revenue Growth 15STAAR Surgical Reports 10% Second Quarter Revenue Growth 16STAAR Surgical Reports 10% Second Quarter Revenue Growth 17STAAR Surgical Reports 10% Second Quarter Revenue Growth 18STAAR Surgical Reports 10% Second Quarter Revenue Growth 19STAAR Surgical Reports 10% Second Quarter Revenue Growth 20STAAR Surgical Reports 10% Second Quarter Revenue Growth 21STAAR Surgical Reports 10% Second Quarter Revenue Growth 22STAAR Surgical Reports 10% Second Quarter Revenue Growth 23STAAR Surgical Reports 10% Second Quarter Revenue Growth 24STAAR Surgical Reports 10% Second Quarter Revenue Growth 25STAAR Surgical Reports 10% Second Quarter Revenue Growth 26STAAR Surgical Reports 10% Second Quarter Revenue Growth 27STAAR Surgical Reports 10% Second Quarter Revenue Growth 28STAAR Surgical Reports 10% Second Quarter Revenue Growth 29STAAR Surgical Reports 10% Second Quarter Revenue Growth 30STAAR Surgical Reports 10% Second Quarter Revenue Growth 31RESMED Inc. Announces Results for the Fourth Quarter and Fiscal Year 2014 2RESMED Inc. Announces Results for the Fourth Quarter and Fiscal Year 2014 3RESMED Inc. Announces Results for the Fourth Quarter and Fiscal Year 2014 4RESMED Inc. Announces Results for the Fourth Quarter and Fiscal Year 2014 5RESMED Inc. Announces Results for the Fourth Quarter and Fiscal Year 2014 6
... Radial Strength, FlexibilityHOUSTON, March 18 IDEV Technologies ... and marketing of minimally invasive technologies, announced today ... has approved an investigational device exemption (IDE) for ... a novel stent platform designed for the treatment ...
... March 18 ULURU Inc. (NYSE Alternext: ULU) ... diabetic foot ulcers, and data on the use of ... presented at the annual DFCon Global Meeting in Los ... presented on posters that will be on display during ...
Cached Medicine Technology:U.S. Food and Drug Administration Clears Way for Multi-Center Clinical Trial of IDEV Technologies' SUPERA Peripheral Stent 2ULURU Inc. to Present Altrazeal(TM) Clinical Evidence and Advanced Therapeutic Research at the Diabetic Foot Global Conference (DFCon) 2009 2ULURU Inc. to Present Altrazeal(TM) Clinical Evidence and Advanced Therapeutic Research at the Diabetic Foot Global Conference (DFCon) 2009 3
(Date:8/1/2014)... 2014 Narrow networks that vary ... employers effective options to trim pharmacy costs and ... they can enhance formulary compliance and achieve savings ... that nearly all PBMs now include a narrow ... The Aug. 12 webinar from Atlantic Information ...
(Date:8/1/2014)... 01, 2014 Millions of women suffer ... legs and in some cases the arms, causing an ... about 17 million women in the U.S. alone are ... with the pain, embarrassment and discomfort caused by lipedema, ... physicians are unaware that this is a disease,” says Dr. ...
(Date:8/1/2014)... August 01, 2014 Get the report ... with PitchBook presents the 3Q 2014 Private Equity Breakdown ... equity investment, exits and fundraising activity in the second ... help plan for private equity endeavors for the remainder ... to download it now. , About Merrill DataSite , ...
(Date:7/31/2014)... 31, 2014 The 2013 edition ... about chemical listings, appellate decisions, litigation and settlement ... affect compliance with California's Proposition 65. , The ... law, regulations, history and trends impacting California's Proposition ... installment of the series which adds approximately 200 ...
(Date:7/31/2014)... recently used birth control pills containing high-dose estrogen and ... breast cancer, whereas women using some other formulations did ... , a journal of the American Association for Cancer ... oral contraceptives [birth control pills] in the past year ... to never or former oral contraceptive use, and that ...
Breaking Medicine News(10 mins):Health News:Atlantic Information Services Webinar to Offer Health Plan, Employer Strategies for Implementing Narrow Pharma Networks 2Health News:Lipedema Centers Works With Insurers To Gain Coverage For Lipedema Treatment 2Health News:Register to Download Merrill DataSite's Report: PitchBook 3Q 2014 Private Equity Breakdown Report 2Health News:Save 25% on the Proposition 65 Handbook - 2013 Edition Through August 31 2Health News:Recent use of some birth control pills may increase breast cancer risk 2
... , WHEATON, Ill., Nov. 24 Dr. Nelson Escobar, ... the recipient of the James Brady Award. The award ... of Illinois during their annual conference on October 30, 2009. ... was given the award in recognition of his expertise in ...
... The Union Labor Life Insurance Company ("Union Labor Life") ... nation,s largest vision benefits and services company, to provide a ... union employers and their members. , VSP has 40,000 doctor ... of optical frames and more. "We understand how important quality ...
... Nov. 24 Centene Corporation (NYSE: CNC ... has selected Centene as one of two Coordinated Care ... (MississippiCAN), a coordinated care program for Mississippi Medicaid beneficiaries. ... a contract in which the company will serve eligible ...
... that pose choking hazard, are too loud, or contain dangerous ... holiday shopping season begins, parents need to know that many ... United States. , That,s the conclusion of the 24th annual ... U.S. Public Interest Research Group (PIRG). , The report focuses ...
... and low-volume centers, study found , TUESDAY, Nov. 24 ... angioplasties necessarily produce the best results for patients? Maybe ... perfect" when it comes to artery-opening procedures, but a ... high-volume hospitals performing more or less equally. , The ...
... have found that hormones produced during pregnancy induce a ... This protein, alpha-fetoprotein (AFP), may serve as a viable, ... cancer, according to findings published in Cancer Prevention ... Cancer Research. "Hormones in pregnancy, such as ...
Cached Medicine News:Health News:Marianjoy Medical Group Physician Receives James Brady Award 2Health News:Union Labor Life & VSP Vision Care Align to Offer Vision Insurance Products 2Health News:Centene Corporation Receives Notification of Intent to Contract From the State of Mississippi 2Health News:Dangerous Toys Still on Store Shelves, Report Finds 2Health News:Dangerous Toys Still on Store Shelves, Report Finds 3Health News:Angioplasty Outcomes May Vary Little Between Hospitals 2Health News:Angioplasty Outcomes May Vary Little Between Hospitals 3Health News:Protein from pregnancy hormone may prevent breast cancer 2
Four disposable disc electrodes are pre-gelled and attached to wires in red, blue, black and green. 4mil carbon film, Ag/AgCl coated. Each package contains 20 individually sealed sets of four leads....
Representing the next step in the evolution of point-of-care testing, the i-STAT 1 Analyzer uses one platform to perform glucose strip testing along with all i-STAT test cartridges....
Lancet cut ultra sharp tip for low penetration resistance. Low noise and impedance level giving you a clear and reliable signal. Stainless steel needle, color coded attached lead wires. Needles sold ...
... bright xenon illumination for ... other instruments. Port allows ... optic cables. Worldwide voltage ... lamp change drawer ...
Medicine Products: